Stock Analysis on Net

Allergan Inc. (NYSE:AGN.)

$22.49

This company has been moved to the archive! The financial data has not been updated since February 19, 2015.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying users area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Allergan Inc., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Notes payable
Convertible notes
Accounts payable
Accrued compensation
Sales rebates and other incentive programs
Royalties
Interest
Sales returns, specialty pharmaceutical products
Legal settlement expenses
Product warranties, breast implant products
Contingent consideration
Investment bank advisory fees
Annual branded prescription drug fee
Restructuring charges
Other
Other accrued expenses
Income taxes
Current liabilities
Long-term debt, excluding current maturities
Postretirement benefit plan
Qualified and non-qualified pension plans
Deferred executive compensation
Deferred income
Contingent consideration
Product warranties, breast implant products
Unrecognized tax benefit liabilities
Other
Other liabilities
Non-current liabilities
Total liabilities
Preferred stock, $.01 par value; none issued
Common stock, $.01 par value
Additional paid-in capital
Accumulated other comprehensive loss
Retained earnings
Treasury stock, at cost
Total Allergan, Inc. stockholders’ equity
Noncontrolling interest
Total equity
Total liabilities and equity

Based on: 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Allergan Inc. current liabilities as a percentage of total liabilities and equity decreased from 2012 to 2013 but then increased from 2013 to 2014 exceeding 2012 level.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Allergan Inc. non-current liabilities as a percentage of total liabilities and equity increased from 2012 to 2013 but then slightly decreased from 2013 to 2014 not reaching 2012 level.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Allergan Inc. total liabilities as a percentage of total liabilities and equity increased from 2012 to 2013 but then slightly decreased from 2013 to 2014 not reaching 2012 level.
Total Allergan, Inc. stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Allergan Inc. total Allergan, Inc. stockholders’ equity as a percentage of total liabilities and equity decreased from 2012 to 2013 but then increased from 2013 to 2014 not reaching 2012 level.